Hutchison MediPharma, a subsidiary of Chi-Med, announced a $12.5 million investment from Mitsui & Co., which received convertible Preference Shares that convert into 12.2% of Hutchison MediPharma. The transaction implies a $100 million valuation for the company, which is the drug discovery arm of Chi-Med. MediPharma said the money would support its various drug development programs. More details....

Stock Symbol: (AIM: HCM)